AKR1B10 and inflammatory bowel disease: Clinical and basic research has proven that AKR1B10 is down-regulated in gastrointestinal cancers and several inflammatory bowel diseases, proposing that its low expression is correlated with poor prognosis and decreased survival for patients with CRC and gastric cancer.